-
「同位素标记抑制剂」(Rac)-Ramosetron-d3 hydrochloride
作者：德尔塔生物 日期：2025-10-20
生物活性：(Rac)-Ramosetron-d3 (hydrochloride) is the deuterium labeled (Rac)-Ramosetron hydrochloride[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：318.82Formula：C17H15D3ClN3O运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (518 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
-
「同位素标记抑制剂」(Rac)-Rotigotine-d7 hydrochloride
作者：德尔塔生物 日期：2025-10-20
生物活性：(Rac)-Rotigotine-d7 (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.IC50 & Target：D1 ReceptorD3 ReceptorD4 Receptor体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(Rac)-Rotigotine-d7 hydrochloride 相关抗体:ADRB2 AntibodyDRD2 AntibodyMTNR1A AntibodyDopamine Receptor D3 Antibody (YA1742)DOPA Decarboxylase Antibody (YA2428)Dopamine Receptor D1 Antibody (YA3270)Salbutamol Antibody (YA901)Clenbuterol Antibody (YA904)alpha 1a Adrenergic Receptor Antibody (YA2059)Torsin 1A Antibody (YA2935)PITX3 Antibody (YA2974)HMBS Antibody (YA3061)分子量：358.98Formula：C19H19D7ClNOS非标记 CAS：102120-99-0运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Subs
-
「同位素标记抑制剂」(S)-5-Hydroxymethyl Tolterodine-d14 formate
作者：德尔塔生物 日期：2025-10-20
生物活性：(S)-5-Hydroxymethyl Tolterodine-d14 (formate) is deuterium labeled (S)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：401.60Formula：C23H19D14NO4非标记 CAS：260389-90-0运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (527 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」(Rac)-Valsartan-d9
作者：德尔塔生物 日期：2025-10-20
生物活性：(Rac)-Valsartan-d9 is deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(Rac)-Valsartan-d9 相关抗体:Natriuretic Peptides A Antibody (YA1381)Angiotensinogen Antibody (YA2097)Natriuretic Peptides B Antibody (YA999)Natriuretic Peptides B Antibody (YA1000)Natriuretic Peptides B Antibody (YA1001)AGTR2 Antibody (YA3090)Angiotensin II Type 1 Receptor Antibody (YA3358)分子量：444.57Formula：C24H20D9N5O3非标记 CAS：137862-53-4中文名称：(Rac)-缬沙坦-d9；(Rac)-丙戊沙坦-d9运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (534 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Shan H, et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014 Jun;18(6):1071-80. [Content Brief][3]. Wang Y,
-
「同位素标记抑制剂」(S)-Pantoprazole-d6
作者：德尔塔生物 日期：2025-10-20
生物活性：(S)-Pantoprazole-d6 is the deuterium labeled (S)-Pantoprazole[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：389.41Formula：C16H9D6F2N3O4S运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (517 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
-
「同位素标记抑制剂」(S)-Cetirizine-d4 dihydrochloride
作者：德尔塔生物 日期：2025-10-20
生物活性：(S)-Cetirizine-d4 (dihydrochloride) is the deuterium labeled (S)-Cetirizine dihydrochloride[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：465.83Formula：C21H23D4Cl3N2O3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (515 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
-
「同位素标记抑制剂」(R)-Methotrexate-d3
作者：德尔塔生物 日期：2025-10-20
生物活性：(R)-Methotrexate-d3 is the deuterium labeled (R)-Methotrexate[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(R)-Methotrexate-d3 相关抗体:ERK1/2 AntibodyE-Cadherin Antibody (YA470)Fatty Acid Synthase Antibody (YA766)DYKDDDDK Tag (FLAG) AntibodyGAPDH AntibodyGFP Antibodyp53 Antibody (YA250)RUNX2 AntibodyFerritin Heavy Chain AntibodyCOX2 AntibodyCtip2 AntibodyCyclin D1 Antibody (YA485)Cytochrome C AntibodyRb AntibodyPhospho-Rb (Ser807) Antibodyc-Myc AntibodyCyclin E1 AntibodyRPA32 Antibody (YA679)AIF Antibody (YA636)ALIX AntibodyCDT1 AntibodyCNPase AntibodyCortactin AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCyclin A2 AntibodyCyclin B1 Antibody (YA486)DNA-PKcs/PRKDC AntibodyDR5 AntibodyDrosha Antibody分子量：457.46Formula：C20H19D3N8O5非标记 CAS：51865-79-3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (517 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」(Rac)-Aprepitant-d4
作者：德尔塔生物 日期：2025-10-20
生物活性：(Rac)-Aprepitant-d4 is the deuterium labeled (Rac)-Aprepitant.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：538.45Formula：C23H17D4F7N4O3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
-
「同位素标记抑制剂」(S)-Stiripentol-d9
作者：德尔塔生物 日期：2025-10-20
生物活性：(S)-Stiripentol-d9 is the deuterium labeled (S)-Stiripentol[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：243.35Formula：C14H9D9O3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (521 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
-
「同位素标记抑制剂」(R)-Stiripentol-d9
作者：德尔塔生物 日期：2025-10-20
生物活性：(R)-Stiripentol-d9 is the deuterium labeled (R)-Stiripentol.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：243.35Formula：C14H9D9O3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (521 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief]
-
「同位素标记抑制剂」Cetirizine-d4 dihydrochloride
作者：德尔塔生物 日期：2025-10-20
生物活性：Cetirizine-d4 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].IC50 & Target：H1 Receptor分子量：465.83Formula：C21H23D4Cl3N2O3非标记 CAS：83881-52-1中文名称：盐酸西替利嗪 d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (535 KB)产品使用指南 (1538 KB)参考文献[1]. Caroline M. Spencer, et al. Cetirizine. Drugs 46 (6): 1055•1080, 1993.[2]. Shih MY, et al. Influence of cetirizine and levocetirizine on two cytokines secretion in human airway epithelial cells. Allergy Asthma Proc. 2008 Sep-Oct;29(5):480-5. [Content Brief][3]. Shimizu T, et al. Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action. Clin Exp Allergy. 2004 Jan;34(1):103-9. [Content Brief]
-
「同位素标记抑制剂」Relugolix-d6
作者：德尔塔生物 日期：2025-10-20
生物活性：Relugolix-d6 is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Relugolix-d6 相关抗体:Prolactin Receptor Antibody (YA2411)Prolactin Antibody (YA1586)GCDFP 15 Antibody (YA2242)分子量：629.67Formula：C29H21D6F2N7O5S非标记 CAS：737789-87-6性状：固体中文名称：瑞卢戈利-d6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month纯度 & 产品资料Data Sheet (521 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Kazuhiro Miwa, et al. Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypy
-
「同位素标记抑制剂」Phenformin-d5 hydrochloride
作者：德尔塔生物 日期：2025-10-20
生物活性：Phenformin-d5 (hydrochloride) is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Phenformin-d5 hydrochloride 相关抗体:AMPK alpha AntibodyPhospho-AMPK alpha 2 (Thr172) AntibodyAMPK alpha 2 Antibody (YA833)Phospho-AMPK alpha 2(Ser345) AntibodyAMPK alpha 1 AntibodyAMPK alpha 1 Antibody (YA624)Phospho-AMPK alpha 1 (Ser496) Antibody (YA226)Phospho-Hormone sensitive lipase (Ser853) AntibodyATF4 Antibody (YA605)AMPK alpha 2 Antibody (YA623)AMPK beta 1 AntibodyAMPK gamma 1 AntibodyATF4 AntibodyPhospho-AMPK alpha 1 (Ser496) AntibodyMARK2 Antibody (YA2104)MARK3 Antibody (YA2150)Phospho-Hormone Sensitive Lipase (Ser855) Antibody (YA2599)分子量：246.75Formula：C10H11D5ClN5非标记 CAS：834-28-6中文名称：盐酸苯乙福明 d5 (盐酸盐)运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (524 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann P
-
「同位素标记抑制剂」Lurbinectedin-d3
作者：德尔塔生物 日期：2025-10-20
生物活性：Lurbinectedin-d3 is deuterium labeled Lurbinectedin. Lurbinectedin (PM01183) is a DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC50 values of 1.25 and 1.16 nM, respectively[1].Clinical TrialNCT NumberSponsorConditionStart DatePhaseNCT05063318PharmaMarAdvanced Solid TumorsOctober 7, 2020Phase 1NCT05734066Jazz PharmaceuticalsRefractory Ewing Sarcoma|Relapsed Ewing Sarcoma|Ewing SarcomaMay 23, 2023Phase 1|Phase 2NCT05876715ERLINDA M GORDON|Sarcoma Oncology Research Center, LLCAdvanced Soft-tissue SarcomaJune 7, 2023Phase 1|Phase 2 NCT05229588HonorHealth Research Institute|Jazz PharmaceuticalsPancreas CancerJune 14, 2022Phase 2NCT00877474PharmaMarADVANCED SOLID TUMORSMarch 2009Phase 1NCT05574504AdventHealth|Jazz PharmaceuticalsMetastatic Cancer|Urothelial CarcinomaMay 8, 2023Phase 2NCT05153239PharmaMarRelapsed Small Cell Lung CancerJuly 22, 2022Phase 3NCT04291937Jazz PharmaceuticalsSmall Cell Lung CancerNCT05126433Jazz PharmaceuticalsAdvanced Solid Tumor|Metastatic Solid Tumor|Urothelial Cancer|Poorly Differentiated Neuroendocrine Carcinomas|Homologous Recombination Deficient-Positive Malignancies AgnosticMarch 3, 2022Phase 2NCT05578326UNC Lineberger Comprehensive Cancer Center|G1 Therapeutics, Inc.Lung Cancer|Small-cell Lung CancerOctober 12, 2022Phase 2NCT05072106PharmaMarAdvanced Solid TumorJanuary 14, 2021Phase 1NCT04610658H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Jazz PharmaceuticalsSmall-cell Lung Cancer|Relapsed Small Cell Lung Cancer|Recurrent Small Cell Lung CancerNov
-
「同位素标记抑制剂」Cabotegravir-d3 sodium
作者：德尔塔生物 日期：2025-10-20
生物活性：Cabotegravir-d3 (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：430.35Formula：C19H13D3F2N3NaO5非标记 CAS：1051375-13-3中文名称：卡博特韦钠-d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (533 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Zhou T, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018 Jan;151:53-65. [Content Brief]
咨询热线
18133906270
德尔塔官方微信